Helix Healthcare Group

INDUSTRIAL IMPACT

Omega Therapeutics, Inc | October 14, 2021

Omega Therapeutics, Inc. ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflamma...

MEDTECH

N2 Biomedical | September 20, 2021

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

FN Media Group | May 08, 2020

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...